Literature DB >> 15556807

The promise of minocycline in neurology.

V Wee Yong1, Jennifer Wells, Fabrizio Giuliani, Steven Casha, Christopher Power, Luanne M Metz.   

Abstract

The capacity of minocycline to alleviate disease for several neurological disorders in animals is increasingly being recognised. Indeed, that one drug alone can attenuate the severity of disease in stroke, multiple sclerosis, spinal-cord injury, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis is astounding. In this review, we describe the evidence for the efficacy of minocycline in several animal models of neurological disease, discuss the mechanisms by which minocycline affects a range of neurological diseases with diverse causes, and introduce the emerging investigation of minocycline in clinical neurology. The encouraging results of minocycline in experimental neurology bode well for its therapeutic use in human neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556807     DOI: 10.1016/S1474-4422(04)00937-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  150 in total

Review 1.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

2.  Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia.

Authors:  Haruyuki Suzuki; Yoshihisa Sugimura; Shintaro Iwama; Hiromi Suzuki; Ozaki Nobuaki; Hiroshi Nagasaki; Hiroshi Arima; Makoto Sawada; Yutaka Oiso
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

3.  Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction.

Authors:  Ann C Rice; Victoria L Chiou; Sarah B Zuckoff; Steven M Shapiro
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 4.  Novel oral agents for multiple sclerosis.

Authors:  Jodie M Burton; Paul O'Connor
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

5.  The CNS as a therapeutic target in multiple sclerosis.

Authors:  Jack P Antel
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

6.  Chemokines and their receptors in intracerebral hemorrhage.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Transl Stroke Res       Date:  2012-04-03       Impact factor: 6.829

7.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

8.  Contribution of macrophages to enhanced regenerative capacity of dorsal root ganglia sensory neurons by conditioning injury.

Authors:  Min Jung Kwon; Jinha Kim; Haeyoung Shin; Soo Ryeong Jeong; Young Mi Kang; Jun Young Choi; Dong Hoon Hwang; Byung Gon Kim
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

9.  Minocycline reduces oxygen-glucose deprivation-induced PC12 cell cytotoxicity via matrix metalloproteinase-9, integrin β1 and phosphorylated Akt modulation.

Authors:  Xiaohong Chen; Shaoqiong Chen; Ying Jiang; Cansheng Zhu; Aimin Wu; Xiaomeng Ma; Fuhua Peng; Lili Ma; Dongliang Zhu; Qing Wang; Rongbiao Pi
Journal:  Neurol Sci       Date:  2012-12-07       Impact factor: 3.307

10.  Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.

Authors:  Xiang Fan; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2013-02-19       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.